Potential strategies could include pharmacological modulation of BA receptors, microbiome-targeted therapies, BA sequestrants, or combination approaches targeting BA signaling in combination with established CLL therapies to enhance disease management. Here, CFB is linked to B-cell chronic lymphocytic leukemia.